Skip to main content
SpringerLink
Log in

Fluoroquinolones in the treatment of cystic fibrosis: A critical appraisal

  • Review
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

While the appropriate usage of antibiotics in cystic fibrosis patients is still a matter of debate, the introduction of oral antipseudomonal antibiotics such as fluoroquinolones represents an eagerly awaited addition to the therapeutic armamentarium. Ciprofloxacin is the single agent most often studied and used in this population for treatment of pulmonary exacerbations. Altered pharmacokinetics of fluoroquinolones have been described in cystic fibrosis patients as for other drugs, and a higher dosage than usual is recommended. Open clinical trials have shown good efficacy of ciprofloxacin in acute infection. A few comparative trials have demonstrated that ciprofloxacin is as effective clinically as conventional intravenous agents. As with other agents, a lack of correlation between clinical improvement and bacteriologic evaluation has been observed. Ciprofloxacin (and possibly ofloxacin) are considered useful alternatives to parenteral agents in therapy of cystic fibrosis patients older than 18 years of age with exacerbations of pulmonary infection. Intermittent therapy with ciprofloxacin alternating with other conventional treatment appears to be a rational approach; clinical trials evaluating the alternation of fluoroquinolones with intravenous anti-pseudomonal therapy are necessary. Considering the potential for emergence of resistance and the not completely elucidated implication of increasing MICs during ciprofloxacin therapy, the duration of treatment should be limited to 2 to 4 weeks. In older children (12 to 18 years old), ciprofloxacin provides an alternative to intravenous agents when clinically justifiable. In view of the possibility of fluoroquinolone associated-arthropathy in younger children, ciprofloxacin should be used judiciously when no alternative agents are available or in life-threatening situations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wood RE, Leigh MW What is a pulmonary exacerbation in cystic fibrosis. Journal of Pediatrics 1987, 8: 841–842.

    Google Scholar 

  2. Gold R, Carpenter S, Heurter H, Corey M, Levison H Randomized trial of ceftazidime versus placebo in the management of acute respiratory exacerbations in patients with cystic fibrosis. Pediatrics 1987, 111: 907–913.

    PubMed  Google Scholar 

  3. Smith AL, Ramsey B, Redding G, Haas J Endobronchial infection in cystic fibrosis. Acta Paediatrica Scandinavica 1989, 363: 31–36.

    Google Scholar 

  4. Bosso JA, Black PG Efficacy of ciprofloxacin in patients with cystic fibrosis. Drug Intelligence and Clinical Pharmacy 1988, 22: 551–553.

    Google Scholar 

  5. Regelmann WE, Elliot GR, Warwick WJ, Clawson CC Reduction of sputumPseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. American Review of Respiratory Diseases 1990, 141: 914–921.

    Google Scholar 

  6. Kerem E, Corey M, Gold R, Levison H Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization withPseudomonas aeruginosa. Journal of Pediatrics 1990, 116: 714–719.

    PubMed  Google Scholar 

  7. Pedersen SS, Jensen T, Pressler T, Hoiby N, Rosendal K Does centralized treatment of cystic fibrosis increase the risk ofPseudomonas aeruginosa infection? Acta Paediatrica Scandinavica 1986, 75: 840–845.

    PubMed  Google Scholar 

  8. Pedersen SS, Jensen T, Hoiby N, Koch C, Flensborg EW Management ofPseudomonas aeruginosa lung infection in Danish cystic fibrosis patients. Acta Paediatrica Scandinavica 1987, 76: 955–961.

    PubMed  Google Scholar 

  9. Guggenbichler JP, Schneeberger J Antimicrobial chemotherapy in patients with cystic fibrosis. Infection 1987, 15: 397–402.

    Article  PubMed  Google Scholar 

  10. Kelly HW Antibiotic use in cystic fibrosis. Drug Intelligence and Clinical Pharmacy 1984, 18: 772–784.

    Google Scholar 

  11. Kuhn RJ, Nahata MC Therapeutic management of cystic fibrosis. Clinical Pharmacy 1985, 4: 555–565.

    PubMed  Google Scholar 

  12. Mouton JW, Kerrebijn KF Antibacterial therapy in cystic fibrosis. Medical Clinics of North America 1990, 74: 836–851.

    Google Scholar 

  13. Hawkey PM Where are we now with ciprofloxacin? Journal of Antimicrobial Chemotherapy 1989, 24: 477–483.

    PubMed  Google Scholar 

  14. Spino M Pharmacokinetics of drugs in cystic fibrosis. Clinical Reviews in Allergy 1991, 9: 169–210.

    PubMed  Google Scholar 

  15. Prandota J Clinical pharmacology of antibiotics and other drugs in cystic fibrosis. Drugs 1988, 35: 542–578.

    PubMed  Google Scholar 

  16. de Groot R, Smith AL Antibiotic pharmacokinetics in cystic fibrosis: differences and clinical significance. Clinical Pharmacokinetics 1987, 13: 228–253.

    PubMed  Google Scholar 

  17. Prandota J Drug disposition in cystic fibrosis: progress in understanding pathophysiology and pharmacokinetics. Pediatric Infectious Diseases Journal 1987, 6: 11–26.

    Google Scholar 

  18. Kearns GL, Reed MD Clinical pharmacokinetics in infants and children. A reappraisal. Clinical Pharmacy 1989, 17, Supplement 1: 29–67.

    Google Scholar 

  19. Smith MJ, White LO, Bowyer H, Willis J, Hodson ME, Batten JC Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis. Antimicrobial Agents and Chemotherapy 1986, 30: 614–616.

    PubMed  Google Scholar 

  20. Goldfarb J, Wormser GP, Inchiosa MA, Guideri G, Diaz M, Gandhi R, Goltzman C, Mascia AV Singledose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis. Journal of Clinical Pharmacology 1986, 26: 222–226.

    PubMed  Google Scholar 

  21. Pedersen SS, Jensen T, Hvidberg EF Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients. Journal of Antimicrobial Chemotherapy 1987, 20: 575–583.

    PubMed  Google Scholar 

  22. Steen HJ, Scott EM, Stevenson MI, Black AE, Redmond AOE, Collier PS Clinical and pharmacokinetic aspects of ciprofloxacin in the treatment of acute exacerbation of pseudomonas infection in cystic fibrosis patients. Journal of Antimicrobial Chemotherapy 1989, 24: 787–795.

    PubMed  Google Scholar 

  23. Bender SW, Dalhoff A, Shah PM, Strehl R, Posselt HG Ciprofloxacin pharmacokinetics in patients with cystic fibrosis. Infection 1986, 14: 17–21.

    Article  PubMed  Google Scholar 

  24. LeBel M, Bergeron MG, Vallée F, Fiset C, Chassé G, Bigonesse P, Rivard G Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients. Antimicrobial Agents and Chemotherapy. 1986, 30: 260–266.

    PubMed  Google Scholar 

  25. Davis RL, Koup JR, Williams-Warren J, Weber A, Heggen L, Stempel D, Smith AL Pharmacokinetics of ciprofloxacin in cystic fibrosis. Antimicrobial Agents and Chemotherapy 1987, 31: 915–919.

    PubMed  Google Scholar 

  26. Sörgel F, Stephan U, Wiesemann HG, Gottschalk B, Stehr C, Rey M, Böwing HB, Dominick HC, Geldmacher von Mallinckrodt M High dose treatment with antibiotics in cystic fibrosis — a reappraisal with special reference to the pharmacokinetics of beta-lactams and new fluoroquinolones in adult CF patients. Infection 1987, 15: 385–396.

    Article  PubMed  Google Scholar 

  27. Reed MD, Stern RC, Myers CM, Yamashita TS, Blumer JL Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis. Journal of Clinical Pharmacology 1988, 28: 691–699.

    PubMed  Google Scholar 

  28. Strandvik B, Hjelte L, Lindblad A, Ljungberg B, Malmborg AS, Nilsson-Ehle I Comparison of efficacy and tolerance of intravenously and orally administered ciprofloxacin in cystic fibrosis patients with acute exacerbations of lung infection. Scandinavian Journal of Infectious Diseases 1989, 60, Supplement: 84–88.

    PubMed  Google Scholar 

  29. Bentur Y, Spino M, Gold R, Tesoro A, Martin S, Pop R, Levy M, Heurter H, MacLeod SM Enhanced ciprofloxacin clearance in cystic fibrosis patients. Clinical Pharmacology and Therapeutics 1990, 47: 185.

    Google Scholar 

  30. Grenier B, Thompson R, Guillot M, Lenoir G, Navarro J, Foucaud P, Reinert P, de la Rocque F, Noel F, Fourtillan JB Use of quinolones in cystic fibrosis. Reviews of Infectious Diseases 1989, 11, Supplement 5: 1245–1252.

    Google Scholar 

  31. Spino M, Bentur Y, Martin S, Heurter H, Brill-Edwards M, Tesoro J, Correia J, Pop R, Gold R, Macleod S: Enoxacin disposition in patients with cystic fibrosis and healthy control subjects. European Journal of Clinical Pharmacology 1989, 169: A84.

  32. Mimeault J, Vallée F, Seelman R, Sorgel F, Ruel M, LeBel M Altered disposition of fleroxacin in patients with cystic fibrosis. Clinical Pharmacology and Chemotherapy 1990, 47: 618–628.

    Google Scholar 

  33. LeBel M Ciprofloxacin: Chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions. Pharmacotherapy 1988, 8: 3–33.

    PubMed  Google Scholar 

  34. Jensen T, Pedersen SS, Nielsen CH, Hoiby N, Koch C The efficacy and safety of ciprofloxacin and ofloxacin in chronicPseudomonas aeruginosa infection in cystic fibrosis. Journal of Antimicrobial and Chemotherapy 1987, 20: 585–594.

    Google Scholar 

  35. Kurz CC, Marget W, Harms K, Bertele RM Kreuzstudie über die Wirksamkeit von Ofloxacin und Ciprofloxacin bei oraler Anwendung. Infection 1986, 14, Supplement: 82–86.

    Article  PubMed  Google Scholar 

  36. Meyer H Ofloxacin in cystic fibrosis. Drugs 1987, 34, Supplement 1: 177–179.

    PubMed  Google Scholar 

  37. Bender SW, Posselt HG, Wonne R, Stover B, Strehl R, Shah PM, Bauernfeind A Ciprofloxacin treatment of patients with cystic fibrosis and pseudomonas bronchopneumonia. In: Neu HC, Weuta H (ed): Proceedings of the First International Ciprofloxacin Workshop. Excerpta Medica, Amsterdam, 1986, p. 272–278.

    Google Scholar 

  38. Smith MJ, Hodson ME, Batten JC Ciprofloxacin in cystic fibrosis. Lancet 1986, i: 1103.

    Article  Google Scholar 

  39. Scully BE, Nakatomi M, Ores C, Davidson S, Neu HC Ciprofloxacin therapy in cystic fibrosis. American Journal of Medicine 1987, 82, Supplement 4A: 196–201.

    PubMed  Google Scholar 

  40. Shalit I, Stutman HR, Marks MI, Chartrand SA, Hilman BC Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis. American Journal of Medicine 1987, 82, Supplement 4A: 189–195.

    Article  Google Scholar 

  41. Goldfarb J, Stern RC, Reed MD, Yamashita TS, Myers CM, Blumer JL Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis. American Journal of Medicine 1987, 82, Supplement 4A: 174–179.

    PubMed  Google Scholar 

  42. Bosso JA, Black PG, Matsen JM Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis. American Journal of Medicine 1987, 82, Supplement 4A: 180–184.

    PubMed  Google Scholar 

  43. Bosso JA, Walker KB Lack of correlation between objective indicators and clinical-response scores during antimicrobial therapy for acute pulmonary exacerbations of cystic fibrosis. Clinical Pharmacy 1988, 7: 897–901.

    PubMed  Google Scholar 

  44. Scully BE, Neu HC, Parry MF, Mandell W Oral ciprofloxacin therapy of infections due toPseudomonas aeruginosa. Lancet 1986, i: 819–822.

    Article  Google Scholar 

  45. Bosso JA Use of ciprofloxacin in cystic fibrosis patients. American Journal of Medicine 1989, 87, Supplement 5A: 123–127.

    Article  PubMed  Google Scholar 

  46. Willems FC, Haverman FEE Long-term oral ciprofloxacin therapy in a cystic fibrosis patient. Lancet 1988, i: 134–135.

    Google Scholar 

  47. Rubio TT Ciprofloxacin: comparative data in cystic fibrosis. American Journal of Medicine 1987, 82, Supplement 4A: 185–188.

    Article  PubMed  Google Scholar 

  48. Hodson ME, Roberts CM, Butland RJA, Smith MJ, Batten JC Oral ciprofloxacin compared with conventional intravenous treatment forPseudomonas aeruginosa infection in adults with cystic fibrosis. Lancet 1987, i: 235–237.

    Article  Google Scholar 

  49. Jensen T, Pedersen SS, Hoiby N, Koch C Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis. European Journal of Clinical Microbiology 1987, 6: 618–622.

    PubMed  Google Scholar 

  50. Schaad UB, Wedgwood-Krucko J, Guenin K, Buchlmann U, Kraemer R Antipseudomonal therapy in cystic fibrosis: aztrconam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin. European Journal of Clinical Microbiology and Infectious Diseases 1989, 8: 858–865.

    Article  Google Scholar 

  51. Pedersen SS Clinical efficacy of ciprofloxacin in lower respiratory tract infections. Scandinavian Journal of Infectious Diseases 1989, 60, Supplement: 89–97.

    PubMed  Google Scholar 

  52. Schaad UB, Wedgwood-Krucko J, Suter S, Kraemer R Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis. Journal of Pediatrics 1987, 111: 599–605.

    PubMed  Google Scholar 

  53. Wolfson JS Quinolone antimicrobial agents: adverse effects and bacterial resistance. European Journal of Microbiology and Infectious Diseases 1989, 8: 1080–1092.

    Google Scholar 

  54. Grimwood K, To M, Rabin HR, Woods DE Inhibition ofPseudomonas aeruginosa exoenzyme expression by subinhibitory antibiotic concentrations. Antimicrobial Agents and Chemotherapy 1989, 33: 41–47.

    PubMed  Google Scholar 

  55. Schaad UB, Wedgwood-Krucko J Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity. Infection 1987, 15: 165–168.

    Article  PubMed  Google Scholar 

  56. Alfaham M, Holt M, Goodchild MC Arthropathy in a patient with cystic fibrosis taking ciprofloxacin. British Medical Journal 1987, 295: 699.

    PubMed  Google Scholar 

  57. Jawad AS Cystic fibrosis and drug-induced arthropathy. British Journal of Rheumatology 1989, 28: 179–180.

    Google Scholar 

  58. Kesseler A, Lacassie A, Hugot JP, Talon P, Thomas D, Astier L Arthropathies following the administration of pefloxacin to an adolescent with mucoviscidosis. Annales de Pédiatrie 1989, 36: 275–278.

    Google Scholar 

  59. Phillips BM, David TJ Pathogenesis and management of arthroplasty in cystic fibrosis. Journal of the Royal Society of Medicine 1986, 79, Supplement 12: 44–60.

    PubMed  Google Scholar 

  60. Adam D Use of quinolones in pediatric patients. Reviews of Infectious Diseases 1989, 11, Supplement 5: 1113–1116.

    Google Scholar 

  61. Stutman HR Summary of a workshop on ciprofloxacin use in patients with cystic fibrosis. Pediatric Infectious Diseases Journal 1987, 6: 932–935.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratoire de Pharmacocinétique Clinique, Ecole de Pharmacie, Université Laval, G1K 7P4, Québec, Québec, Canada

    M. LeBel

Authors
  1. M. LeBel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

LeBel, M. Fluoroquinolones in the treatment of cystic fibrosis: A critical appraisal. Eur. J. Clin. Microbiol. Infect. Dis. 10, 316–324 (1991). https://doi.org/10.1007/BF01967005

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01967005

Keywords

Search

Navigation